Akums Drugs and Pharmaceuticals Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹646 - ₹679
- Lot size
- 22 shares
- Issue amount
- ₹1,856.74 cr
- Total subscription
- 63.56×
- Opens
- 30 Jul 2024
- Closes
- 1 Aug 2024
- Allotment
- 2 Aug 2024
- Listing
- 6 Aug 2024
Offer at a glance
Issue overview
- Issue size
- 2,73,68,143 shares
- Face value
- ₹2 per share
- Minimum investment
- ₹14,212
- Fresh issue
- ₹680.99 cr
- Offer for sale
- ₹1,175.75 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,938
- Issue type
- Bookbuilding IPO
- Shares before issue
- 14,73,56,280
- Shares after issue
- 15,73,71,007
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 22 | ₹14,938 |
| sHNI | 14 | 308 | ₹2,09,132 |
| bHNI | 67 | 1,474 | ₹10,00,846 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| HNIs(10L +) | 8,807 | 84,932 |
| HNIs (2-10L) | 4,403 | 1,35,305 |
| RETAIL | 1,23,292 | 21,04,030 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 552.52 | 49,778.7 |
| RETAIL | 184.17 | 3,922.58 |
| NIB | 276.26 | 11,661.83 |
| HNIs 2+ | 92.09 | 2,926.52 |
| HNIs 10+ | 184.17 | 8,735.31 |
| EMPLOYEES | 16.56 | 70.7 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|
| EPS | 0.28 | 6.63 | -17.65 |
| ROE | 0.11 | 13.52 | -40.13 |
| ROCE | 3.37 | 24.6 | -18.89 |
| RONW | -0.57 | 13.23 | -40.6 |
| PRE IPO(PE) | 0 | 0 | 0 |
| POST IPO(PE) | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading pharmaceutical CDMO providing end-to-end solutions in product development, manufacturing, R&D, regulatory dossier preparation, and testing for domestic and international markets. The company manufactures and sells branded drugs and APIs, with a diverse portfolio that includes tablets, capsules, liquids, injectables, eye drops, topicals, and even gummy bears. Akums has commercialized 4,025 formulations across more than 60 dosage forms and served 26 of India’s top 30 pharmaceutical companies by revenue in FY 2023. With 10 manufacturing units offering a combined annual capacity of 49.21 billion units and plans to commission two more by FY 2025, the company continues to scale its operations. Many of its facilities are accredited by global regulatory authorities such as EU-GMP, WHO-GMP, and US NSF. As of September 30, 2023, Akums employed 16,463 personnel, including 7,211 full-time and 9,252 contract staff.
Strengths
- Market Leader: Akums Drugs and Pharmaceuticals Limited is India's largest company focused on providing contract development and manufacturing services (CDMO) to the domestic pharmaceutical market (Source: F&S Report).
- Trusted by Top Brands: The company partners with 26 of the top 30 pharmaceutical companies in India by revenue in FY 2023, building long-term, trusted relationships.
- Strong R&D Strength: Akums has a fast-growing research and development team that continuously works on creating innovative products across its wide product portfolio.
Risk factors
- Geographic Concentration: Akums' manufacturing units and R&D centers are mainly located in Haridwar, Uttarakhand. This makes the company vulnerable to economic, political, regulatory changes, or natural disasters in the region, which could affect its business operations and financial stability.
- Operational Disruptions: If Akums' manufacturing or R&D operations slow down or temporarily shut down, it could hurt the company's business performance, profits, and cash flow.
- Regulatory Compliance: Regular inspections and audits by regulatory authorities or clients may result in penalties or actions that could damage Akums' reputation and negatively impact its business, profits, and financial health.
Promoters
Sanjeev Jain
Sandeep Jain
Akums Master Trust
Registrar & documents
Lead manager
ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, Ambit Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034
+91 11 6904 1000
[email protected]Company website ↗Understanding AKUMS IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.